全文获取类型
收费全文 | 2908篇 |
免费 | 249篇 |
国内免费 | 182篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 6篇 |
妇产科学 | 7篇 |
基础医学 | 60篇 |
口腔科学 | 4篇 |
临床医学 | 287篇 |
内科学 | 1077篇 |
皮肤病学 | 1篇 |
神经病学 | 8篇 |
特种医学 | 416篇 |
外国民族医学 | 4篇 |
外科学 | 269篇 |
综合类 | 506篇 |
预防医学 | 49篇 |
药学 | 159篇 |
中国医学 | 42篇 |
肿瘤学 | 443篇 |
出版年
2024年 | 3篇 |
2023年 | 73篇 |
2022年 | 133篇 |
2021年 | 190篇 |
2020年 | 193篇 |
2019年 | 113篇 |
2018年 | 140篇 |
2017年 | 146篇 |
2016年 | 152篇 |
2015年 | 183篇 |
2014年 | 273篇 |
2013年 | 237篇 |
2012年 | 188篇 |
2011年 | 211篇 |
2010年 | 165篇 |
2009年 | 196篇 |
2008年 | 140篇 |
2007年 | 139篇 |
2006年 | 108篇 |
2005年 | 99篇 |
2004年 | 51篇 |
2003年 | 48篇 |
2002年 | 33篇 |
2001年 | 29篇 |
2000年 | 28篇 |
1999年 | 15篇 |
1998年 | 15篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 10篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有3339条查询结果,搜索用时 15 毫秒
1.
2.
《European journal of surgical oncology》2022,48(5):956-966
BackgroundA comprehensive re-evaluation on the role of trans-arterial chemoembolization (TACE) in patients with intrahepatic cholangiocarcinoma.MethodsA thorough database searching was performed in PubMed, EMBASE, and the Cochrane Library. Eligible studies were restricted to comparative studies between TACE and non-TACE cohorts. RevMan5.3 software and Stata 13.0 software were used for statistical analyses. The primary endpoint of our study was long-term survival.ResultsA total of 11 studies with 2036 patients were finally identified. Pooled results revealed that patients receiving TACE had a significantly better overall survival (OS) versus those without TACE (P < 0.05). Subgroup analyses were performed according to different types of TACE. Prophylactic post-surgical TACE (PPTACE) was associated with a significantly better OS versus those without PPTACE (P < 0.05). Palliative TACE (PTACE) also achieved a significantly better OS compared with those with supportive treatment (ST) only (P < 0.00001). However, TACE had no impact on disease-free survival (P = 0.87) and was less effective than surgical resection (P = 0.003).ConclusionPPTACE has a remarkable impact on OS versus those with surgical resections only and should be regularly performed. Regarding patients with unresectable disease, apart from conventional ST, adjuvant PTACE is also recommended. Upcoming prospective randomized controlled trials are warranted for further validation. 相似文献
3.
《Arab Journal Of Gastroenterology》2022,23(1):32-38
Background and study aimsA full understanding of the clinical manifestations and risk factors for hepatic abscesses with biloma formation after transcatheter arterial chemoembolization (TACE) is crucial for accurate diagnosis and effective therapeutic intervention.Patients and methods11,524 patients with hepatic tumors were treated with TACE. 84 patients were diagnosed with hepatic abscesses after TACE, and 35 progressed to hepatic bilomas and were treated with percutaneous transhepatic drainage (PTD) and/or percutaneous transhepatic cholangiography and drainage (PTCD). Clinical features, blood samples, bacterial cultures, and imaging data were collected, and incidence, risk factors, therapeutic effects, and prognostic indicators were analyzed.ResultsThe incidence of biloma in patients with liver abscesses was 41.7% with an average diagnosis time of 12.3 ± 3.2 days. 71.4% of patients complained of abdominal pain, and 63.7% had metastatic liver cancer. In the latter patients, clinical features included multiple abscess lesions with a poor blood supply to the tumor and large necrotic lesions. The original tumors were primarily in the digestive system (87.0%). The mean diameter of the largest lesions was 6.5 ± 2.3 cm. Before abscess formation, the Child-Pugh liver function classification was grade A in 14 cases and grade B in 21 cases. Escherichia coli was the most frequently seen infectious bacteria. Liver function was significantly compromised by the occurrence of hepatic abscesses. The mean survival time after diagnosis of liver abscesses in all patients was 11.5 ± 0.6 months. The causes of death included abscess (n = 9, 25.7%), tumor (n = 22, 62.9%), and other causes (n = 4, 11.4%). Risk factors included tumors, gastrointestinal surgery, and diabetes.ConclusionPTD and/or PTCD combined with active antibiotics are recommended as the first-line treatment and are effective therapeutic regimens for biloma formation after TACE. 相似文献
4.
目的 探讨动态对比增强磁共振成像(DCE-MRI)检查诊断原发性肝癌(PLC)患者的效能及评价疗效的价值。方法 2017年1月~2021年6月我院诊治的肝占位性病变患者68例,均接受DCE-MRI检查,并行穿刺细胞学检查诊断,应用临床流行病学基本技术评估MRI诊断的效能。所有PLC患者接受经皮肝动脉化疗栓塞术(TACE)治疗,术后再次接受MRI检查,评估疗效。结果 DCE-MRI检查显示PLC患者肝内特征性恶性肿瘤表现,T1WI序列为低信号,T2WI序列为高信号,动脉期明显强化,门脉期快速消退,偶见明显的肿瘤包膜;在68例肝占位性病变患者,经穿刺细胞学检查,诊断PLC患者64例,非肿瘤病变4例;DCE-MRI检查诊断的灵敏度、特异度、准确率、阳性和阴性预测值分别为95.2%、75.0%、89.7%、93.8%和25.0%;在TACE术后,MRI检查发现肿瘤被完全灭活18例(28.1%),部分灭活25例(39.1%),肿瘤稳定15例(23.4%),疾病进展6例(9.3%)。结论 DCE-MRI检查在诊断PLC和治疗后疗效判断方面有独特的作用,可指导临床制定治疗方案,价值很大。 相似文献
5.
目的观察肝癌TACE术注入栓塞剂前应用利多卡因联合规范围手术期护理,对包括老年人群在内的肝癌患者的镇痛效果及对睡眠和生活质量的影响。 方法将100例拟行TACE术肝癌患者,按入院先后顺序分为两组各50例。两组均给予规范围手术期护理,观察组在TACE术中注入栓塞剂前一次性注入盐酸利多卡因注射液100 mg,对照组在注入栓塞剂前不注入利多卡因。两组均采用疼痛评分(视觉模拟评分法)、癌症患者生活质量量表、Spiegel量表评估两组术前、术后24 h疼痛、生活质量、睡眠情况。 结果两组术前生活质量评分、Spiegel量表评分比较及疼痛评分均无统计学意义(P > 0.05)。术后24 h生活质量评分,观察组(35.08 ± 9.50)与对照组(38.72 ± 10.9)比较无统计学意义(P > 0.05),观察组优于对照组;术后24 h Spiegel量表评分,观察组(11.56 ± 2.31)与对照组(9.02 ± 2.69)比较均有统计学意义(P < 0.001),观察组优于对照组;术后24 h疼痛视觉模拟评分,观察组(2.38 ± 1.47)与对照组(4.08 ± 1.59)比较有统计学意义(P < 0.001),观察组优于对照组。 结论TACE术中注入栓塞剂前应用利多卡因联合规范围手术期护理,可以减轻肝癌患者包括老年人群在内的术后疼痛,改善其睡眠质量。 相似文献
6.
【摘要】 目的 探讨CT放射组学列线图模型预测CalliSpheres药物洗脱微球- 经导管动脉栓塞术(DEB- TACE)治疗肝细胞癌(HCC)生存期的价值。方法 回顾性分析2016年1月至2018年12月经穿刺病理或临床诊断为HCC,且巴塞罗那临床肝癌B期(BCLC- B)行DEB- TACE的100例患者(训练组60例,测试组40例)。利用A.K.软件进行术前CT影像组学特征提取,并将选定的特征与相应的非零系数相乘的线性组合来计算每个患者的放射组学评分(Rad- score)。Cox回归分析与术后生存相关的独立危险因素。根据独立危险因素,共建立5个预测模型,并进行模型间AUC比较,选出最佳预测模型。以最佳预测模型生成影像组学列线图,并用校准图形法直观表示其预测符合度。结果 100例患者中,存活52例,死亡48例。肿瘤数目、GGT、Rad-score值是影响DEB- TACE治疗HCC术后生存期的独立危险因素,临床- 静脉期影像组学联合模型在训练组和验证组中的AUC及准确率最高(训练组AUC=0.921,准确率84.4%;验证组AUC=0.904,准确率81.5%),为最佳模型。该模型在训练组和验证组中都显示出良好的校正能力。结论 术前CT影像组学列线图模型对预测DEB- TACE治疗BCLC- B期HCC生存期具有价值。 相似文献
7.
Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization 下载免费PDF全文
Nakarin InmuttoNatthaphong NimitrungtaweeTanop SrisuwanThanate KattipathanapongAttaporn JantarangkoonOranit Puttisri 《Asian Pacific journal of cancer prevention》2022,23(11):3939-3946
Background: Transarterial chemoembolization (TACE) is one of the locoregional treatments for intermediate-stage hepatocellular carcinoma (HCC). Multidetector computed tomography (MDCT) is a widely used diagnostic tool for HCC. It can also evaluate tumor size, tumor number, and tumor invasion. This study aimed to determine the median survival time in intermediate-stage HCC patients who underwent TACE and to find out prognostic factors influencing patients’ survival time after TACE. Methods: A computerized search of medical record database in Maharaj Nakorn ChiangMai Hospital from January 2016 to December 2019 revealed 187 intermediate-stage HCC patients who received TACE as the first-line treatment. Results: The median survival time of patients in this study was 9.9 months (95% CI: 8.3-11.6). The patients with aspartate aminotransferase-to-platelet ratio (APRI) less than 0.5 had a significantly better median survival time as compared with patients with APRI ratio more than 0.5; (13.2 months versus 9.9 months, p-value < 0.05). Univariate and multivariate Cox regression analysis demonstrated that tumor number > 7 and tumor size > 5 centimeters (cm) could be considered as independent parameters predicting poor overall survival time in the sufferers (HR 2.64 95%CI 1.68-4.15 and HR 2.38 95%CI 1.32-4.31, respectively). Conclusion: Based on our findings, patients with intermediate-stage HCC who received TACE had a lower median survival time compared to previous studies. However, we identified APRI less than 0.5, tumor size less than 5 cm, and tumor number less than 7 as prognostic factors improving survival time in intermediate-stage HCC patients. 相似文献
8.
9.
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(5):510-517.e1
PurposeThe albumin-bilirubin (ALBI) grade has been established as an improved predictor of survival in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization and yttrium-90 radioembolization. The purpose of the study was to investigate the utility of ALBI grade in prognosticating outcomes in patients with HCC treated with drug-eluting embolic (DEE) transarterial chemoembolization (TACE).Materials and MethodsA single-center retrospective review was performed to compare the efficacy of ALBI grade and Child-Pugh (CP) classification in predicting the survival of patients with HCC receiving DEE-TACE. A total of 303 patients with HCC were identified who had received DEE-TACE without concomitant locoregional therapy within 30 days. Survival analysis was performed using Kaplan-Meier methods and censored for curative therapy. Survival curves were stratified based on the ALBI grade, CP class, Barcelona Clinic Liver Cancer (BCLC) stage, Eastern Cooperative Oncology Group performance status, and presence of ascites. The discriminatory ability of survival curves was calculated by C-Index.ResultsKaplan-Meier survival curves stratified by the ALBI grade produced distinct, nonoverlapping curves (P < .001), showing greater discriminatory ability than the CP classification (C-index = 0.568 and 0.545, respectively). The substratification of the BCLC stage by the ALBI grade yielded greater discriminatory ability than the substratification by the CP classification (C-index = 0.573 and 0.565, respectively). For patients with BCLC stage B, the substratification by the ALBI grade yielded distinct curves, whereas the substratification by the CP classification did not (P = .011 and P = .379, respectively).ConclusionsALBI grade showed improved discriminatory ability compared with CP classification in differentiating overall survival among patients with HCC receiving DEE-TACE. Furthermore, ALBI grade was effective in substratifying survival among patients categorized as CP class A and patients with BCLC stage B, whereas CP classification was not effective. 相似文献